ArticlePharmacotherapy2026
Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?
Article in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?Pharmacotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of apixaban prior to kidney transplantation is on the rise. However, optimal perioperative management remains uncertain, particularly regarding the need for preoperative reversal with four-factor prothrombin complex concentrate (4F-PCC). Prior reports suggest clinically relevant bleeding without reversal, but potential thrombotic consequences of prophylactic 4F-PCC warrant caution. We hypothesized that withholding preoperative 4F-PCC in patients taking apixaban before kidney transplantation would not increase early postoperative surgical-bed bleeding.
methodsThis retrospective, two-center study included adult kidney transplant recipients (KTRs) from January 2019 to September 2025 who had taken apixaban within 48 h before surgery. Patients were stratified by receipt versus nonreceipt of preoperative 4F-PCC. The primary endpoint was surgical-bed bleeding within 3 days of transplant. A one-sided noninferiority test (margin of 15%) was used for the primary endpoint.
resultsFifty KTRs were included, and 14 (28%) received preoperative 4f-PCC and 36 (72%) did not. The median time since the last known apixaban dose was 21 h (interquartile range [IQR], 16-24 h) before transplant. Surgical-bed bleeding occurred in 7.1% in the preoperative 4F-PCC cohort and in 5.6% of the no preoperative 4F-PCC cohort (differences, 1.6%; upper one-sided confidence interval [CI], 21.5%; p = 0.11), suggesting similar event rates but not confirming noninferiority. No significant differences were observed between groups in transfusion requirements, delayed graft function, kidney function, venous thromboembolism (1 in the reversal group; 0 in the non-reversal group), or reoperation. Two deaths occurred in the reversal group.
conclusionsWithholding preoperative 4F-PCC in apixaban-treated KTR appears safe, with surgical-bed bleeding rates comparable to those in patients who received preoperative 4F-PCC. Findings support individualized rather than routine preoperative reversal strategies to balance bleeding and thrombotic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.